Outcomes and Practice Preferences After Endophthalmitis Following Anti-VEGF Intravitreal Injection. (November 2019)
- Record Type:
- Journal Article
- Title:
- Outcomes and Practice Preferences After Endophthalmitis Following Anti-VEGF Intravitreal Injection. (November 2019)
- Main Title:
- Outcomes and Practice Preferences After Endophthalmitis Following Anti-VEGF Intravitreal Injection
- Authors:
- Chen, Yicheng
Shah, Gaurav K.
Shah, Vaishali
Blinder, Kevin J.
Jeroudi, Abdallah M.
Leonard, Anthony
Gilca, Marina
Pollack, John S.
Wang, Rui
Wykoff, Charles C.
Weinstock, Brett M.
Regillo, Carl D.
van Zyl, Tave
Modjtahedi, Bobeck S.
Eliott, Dean
Kalevar, Ananda
Jumper, J. Michael
Whitted, Ryan J.
Lee, Gregory
Kitchens, John W.
Joseph, Anthony
Heier, Jeffrey S.
Rostamizadeh, Mahdi
Abdelaziz, Musa
Singerman, Lawrence J.
Hu, Jonathan K.
Tewari, Asheesh - Abstract:
- Purpose: This study examines treatment-based outcomes of endophthalmitis due to antivascular endothelial growth factor (anti-VEGF) intravitreal injection and its effect on subsequent management of neovascular disease. Methods: A retrospective multicenter study was conducted of 157 patients with a diagnosis of endophthalmitis following anti-VEGF intravitreal injection at 10 major ophthalmic centers. Results: The median number of injections before endophthalmitis was 10 (range, 1 to 84 injections). Initial treatment with tap and inject with or without subsequent vitrectomy trended toward smaller visual acuity changes from baseline (4 ETDRS [Early Treatment Diabetic Retinopathy Study] letter difference vs 19 ETDRS letter difference) compared with initial vitrectomy, but the difference was not statistically significant. There was no significant change in medication choice among injections after endophthalmitis. There was a statistically significant shift away from regular interval (1- to 2-month) injections and a shift toward treat-and-extend and as-needed injection algorithms. Conclusions: The visual outcomes were not significantly different between patients who initially underwent tap and injection of antibiotics and those who underwent vitrectomy. There was no significant change in medication choice before and after endophthalmitis but there was a shift toward lower-frequency injection algorithms after postintravitreal injection endophthalmitis compared with prior.
- Is Part Of:
- Journal of vitreoretinal diseases. Volume 3:Number 6(2019)
- Journal:
- Journal of vitreoretinal diseases
- Issue:
- Volume 3:Number 6(2019)
- Issue Display:
- Volume 3, Issue 6 (2019)
- Year:
- 2019
- Volume:
- 3
- Issue:
- 6
- Issue Sort Value:
- 2019-0003-0006-0000
- Page Start:
- 411
- Page End:
- 419
- Publication Date:
- 2019-11
- Subjects:
- anti-VEGF agents -- central retinal vein occlusion -- choroidal neovascularization -- diabetic macular edema -- endophthalmitis -- retinal neovascularization -- vitreoretinal surgery -- wet AMD (neovascular)
Retina -- Diseases -- Periodicals
Vitreous body -- Diseases -- Periodicals
Retina -- Diseases
Vitreous body -- Diseases
Periodicals
617.735005 - Journal URLs:
- http://journals.sagepub.com/toc/VRD/current ↗
https://uk.sagepub.com/en-gb/eur/journal-of-vitreoretinal-diseases/journal202603 ↗
http://www.sagepublications.com/ ↗ - DOI:
- 10.1177/2474126419858492 ↗
- Languages:
- English
- ISSNs:
- 2474-1264
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 11804.xml